Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients

Haematologica

Volumn 98, Issue 9, 2013, Pages 1481-1486

  Henrard, Séverine ^a,b   Speybroeck, Niko ^a   Hermans, Cedric ^b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADULT; ARTICLE; BODY HEIGHT; BODY MASS; FAT MASS; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; MORPHOMETRICS; OBESITY; REGRESSION ANALYSIS; UNDERWEIGHT;

ADULT; BODY MASS INDEX; COHORT STUDIES; FACTOR VIII; FEMALE; HEMOPHILIA A; HUMANS; MALE; OVERWEIGHT; THINNESS; YOUNG ADULT;

EID: 84883627178     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.084038     Document Type: Article

References (12)

1. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003;361(9371):1801-9.
2. Björkman S, Berntorp E. Pharmacokinetics of coagulation factors. Clinical relevance for patients with haemophilia. Clin Pharmacokinet. 2001;40(11):815-32.
3. Henrard S, Speybroeck N, Hermans C. Body weight and fat mass index as strong predictors of factor VIII in vivo recovery in adults with hemophilia A. J Thromb Haemost. 2011;9(9):1784-90.
4. Deurenberg P, Weststrate JA, Seidell JC. Body mass index as a measure of body fatness: Age-and sex-specific prediction formulas. Br J Nutr. 1991;65(2):105-14.
5. Speybroeck N. Classification and regression trees. Int J Public Health. 2012;57(1):243-6.
6. Marshall RJ. The use of classification and regression trees in clinical epidemiology. J Clin Epidemiol. 2001;54(6):603-9.
7. Ingram GI. Calculating the dose of factor VIII in the management of haemophilia. Br J Haematol. 1981;48(2):351-4.
8. Björkman S, Blanchette VS, Fischer K, Oh M, Spotts G, Schroth P, et al. Comparative pharmacokinetics of plasma-and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost. 2010;8(4):730-6.
9. Blanchette VS, Shapiro AD, Liesner RJ, Hernández Navarro F, Warrier I, Schroth PC, et al. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost. 2008;6(8): 1319-26.
10. Collins PW, Fischer K, Morfini M, Blanchette VS, Björkman S, on behalf of the international prophylaxis study group (ISPG) pharmacokinetics expert working group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia. 2011;17(1):2-10.
11. Wong TE, Majumdar S, Adams E, Bergman S, Damiano ML, Deutsche J, et al. Overweight and obesity in hemophilia: a systematic review of the literature. Am J Prev Med. 2011;41(6 Suppl 4):S369-75.
12. Knobe K, Berntorp E. New treatments in hemophilia: insights for the clinician. Ther Adv Hematol. 2012;3(3):165-75.